Clinical Trial

Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL

Name: Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL — clinical trial record (NCT07244406)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the efficacy and safety of S1904 in patients with relapsed or refractory CD19+B-ALL.

Trial Details

NCT Number	NCT07244406
Lead Sponsor	Hebei Senlang Biotechnology Inc., Ltd.
Conditions	B-ALL
Enrollment	59 participants
Start Date	2025-01-10
Primary Completion	2027-03-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-11-24